This company listing is no longer active
NK8 Stock Overview
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
NuVasive, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.80 |
| 52 Week High | US$48.00 |
| 52 Week Low | US$33.80 |
| Beta | 1.07 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -12.38% |
| 3 Year Change | -14.02% |
| 5 Year Change | -37.81% |
| Change since IPO | 315.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| NK8 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 2.8% | -3.9% | -1.4% |
| 1Y | -12.4% | -14.0% | 15.4% |
Return vs Industry: NK8 underperformed the German Medical Equipment industry which returned -10.7% over the past year.
Return vs Market: NK8 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| NK8 volatility | |
|---|---|
| NK8 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: NK8 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine NK8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,000 | Chris Barry | www.nuvasive.com |
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room.
NuVasive, Inc. Fundamentals Summary
| NK8 fundamental statistics | |
|---|---|
| Market cap | €1.94b |
| Earnings (TTM) | €26.41m |
| Revenue (TTM) | €1.14b |
73.3x
P/E Ratio1.7x
P/S RatioIs NK8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NK8 income statement (TTM) | |
|---|---|
| Revenue | US$1.23b |
| Cost of Revenue | US$347.50m |
| Gross Profit | US$878.73m |
| Other Expenses | US$850.28m |
| Earnings | US$28.45m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 71.66% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 89.1% |
How did NK8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/02 08:27 |
| End of Day Share Price | 2023/08/31 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NuVasive, Inc. is covered by 39 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |